GlassScriptPhysician profile
Gregory Haselhuhn
NPI 1538145560
$538.71
in general payments reported to CMS, 2019-2025
13 companies · $17.88 in 2025
The $17.88 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2021: $267 · 2022: $27.00 · 2023: $18.78 · 2025: $17.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $18.78 · Food and Beverage: $17.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $18.78 |
| Food and Beverage | $17.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $126.86 | 2019-2021 | |
| Janssen Biotech, INC. | $90.15 | 2019-2021 | |
| Myovant Sciences INC. | $66.82 | 2021 | |
| Pfizer INC. | $43.12 | 2019-2023 | |
| Blue Earth Diagnostics | $39.71 | 2019 | |
| Teleflex LLC | $38.43 | 2021 | |
| Boston Scientific Corporation | $29.39 | 2021-2025 | Lynx System |
| Abbvie INC. | $27.00 | 2022 | |
| Travere Therapeutics, INC. | $23.19 | 2021-2023 | Thiola |
| Endo Pharmaceuticals INC. | $21.56 | 2019 | |
| Urovant Sciences INC | $16.62 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Haselhuhn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.